Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating expenses:      
Research and development, including stock-based compensation of $469,357, $626,002 and $451,334, respectively $ 18,057,025 $ 22,416,651 $ 17,314,086
General and administrative, including stock-based compensation of $977,192, $929,521 and $1,171,794, respectively 9,809,423 8,707,774 9,249,671
Total operating expenses 27,866,448 31,124,425 26,563,757
Loss from operations (27,866,448) (31,124,425) (26,563,757)
Other income (expense):      
Interest income 359,270 672,227 418,135
Other expense     (905,014)
Change in fair value of warrant liabilities 14,712,685 (7,232,226) 11,532,978
Total other income (expense) 15,071,955 (6,559,999) 11,046,099
Net loss $ (12,794,493) $ (37,684,424) $ (15,517,658)
Per share information:      
Net loss per share of common stock, basic and diluted $ (1.54) $ (4.95) $ (2.79)
Basic and diluted weighted average shares outstanding 8,283,509 7,606,266 5,559,573